Meghan Lubner
Papers
1
Total Citations
30
H-Index
1
About
Meghan Lubner is a pioneering researcher in interventional oncology, with a primary focus on the development and clinical translation of histotripsy—a novel, noninvasive, non-thermal focused ultrasound technology that mechanically liquefies targeted tissue. Her most notable contribution is leading the landmark #HOPE4LIVER single-arm pivotal trial, which evaluated the one-year clinical outcomes of hepatic histotripsy for treating primary and metastatic liver tumors. This groundbreaking work, published in 2025 and already garnering over 30 citations, demonstrates the safety and efficacy of a technique that spares healthy liver parenchyma while precisely destroying tumors. Lubner’s research bridges the gap between engineering innovation and patient care, offering a promising alternative to surgery, radiation, or thermal ablation for liver cancer patients. Her work has positioned histotripsy as a transformative tool in the fight against liver malignancies, with potential applications beyond the liver. Through rigorous clinical trials and translational studies, Lubner continues to shape the future of noninvasive cancer therapy, earning recognition as a leader in the field of image-guided tumor ablation.
Research Focus
Key Achievements
Top Papers
- 1